Estrella Immunopharma, Inc. carries no debt; cash flow comfortably covers obligations.

Estrella Immunopharma, Inc.'s free cash flow has increased -88.89% from $-16.07M last year to $-1.79M, signaling increasing performance

Estrella Immunopharma, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Estrella Immunopharma, Inc. has insufficient data to evaluate this check.

Estrella Immunopharma, Inc. has a net cash position, so leverage is healthy.

Estrella Immunopharma, Inc. carries no debt; interest obligations are fully covered.

Estrella Immunopharma, Inc. has insufficient data to evaluate this check.

Estrella Immunopharma, Inc.'s short-term liabilities of $13.54M exceed its short-term assets of $1.68M, signaling financial risk

Estrella Immunopharma, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Estrella Immunopharma, Inc.'s return on equity of 167.91%, is higher than 15.00%, indicating good performance

Estrella Immunopharma, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Estrella Immunopharma, Inc. has insufficient public price history to evaluate earnings stability.

Estrella Immunopharma, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Estrella Immunopharma, Inc. has negative free cash flow, indicating cash burn

Estrella Immunopharma, Inc.'s yearly earnings has decreased 47.65% since last year from $-8.85M to $-13.06M, signaling decreasing performance

Estrella Immunopharma, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC 251.42% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.

Estrella Immunopharma, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Estrella Immunopharma, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Estrella Immunopharma, Inc. has insufficient public price history to evaluate ROE consistency.

Estrella Immunopharma, Inc. has insufficient data to evaluate this check.

Estrella Immunopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Estrella Immunopharma, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Estrella Immunopharma, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Estrella Immunopharma, Inc. has insufficient data to evaluate this check.

Estrella Immunopharma, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Estrella Immunopharma, Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Estrella Immunopharma, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue